Apoprotein(a) (Apolipoprotein (a))

A large and highly glycosylated protein constituent of LIPOPROTEIN (A). It has very little affinity for lipids but forms disulfide-linkage to APOLIPOPROTEIN B-100. Apoprotein(a) has SERINE PROTEINASE activity and can be of varying sizes from 400- to 800-kDa. It is homologous to PLASMINOGEN and is known to modulate THROMBOSIS and FIBRINOLYSIS.

Also Known As:

Networked: 555 relevant articles (8 outcomes, 65 trials/studies)

Relationship Network

Bio-Agent Context: Research Results

Experts

1.	Marcovina, Santica M: 11 articles (05/2013 - 03/2002)
2.	Yoon, Yeup: 9 articles (06/2014 - 08/2003)
3.	Geroldi, Diego: 9 articles (04/2005 - 08/2002)
4.	Kim, Jang-Seong: 8 articles (06/2014 - 08/2003)
5.	Yu, Hyun-Kyung: 8 articles (06/2014 - 08/2003)
6.	Peros, Emmanouil: 8 articles (04/2005 - 12/2003)
7.	Lee, Ho-Jeong: 7 articles (06/2014 - 10/2004)
8.	Ahn, Jin-Hyung: 7 articles (01/2014 - 08/2003)
9.	Emanuele, Enzo: 7 articles (04/2005 - 12/2003)
10.	Kronenberg, Florian: 6 articles (10/2015 - 01/2003)

Related Diseases

1.	Stroke (Strokes) 01/01/2001 - "The aim of this work was the determination of apolipoprotein(a) [Lp(a)] in the patients three months after the onset of ischaemic stroke. " 01/01/1999 - "Apolipoprotein(a) size polymorphism in young adults with ischemic stroke." 06/01/1993 - "Restriction fragment length polymorphism of the apoprotein A-I-C-III gene cluster in control and stroke-prone white and black subjects: racial differences." 09/01/1992 - "Restriction fragment length polymorphism of the apoprotein A-I-C-III gene cluster in control and stroke-prone white and black subjects: racial differences." 05/01/2004 - "The aim of the work was to recognize whether often observed high levels of apolipoprotein (a) [Lp(a)] in patients shortly after an ischemic stroke are a result of the acute phase reaction. "
2.	Atherosclerosis 09/01/2012 - "We showed that human apolipoprotein A-V is a potent modulator of atherosclerosis in mice through multiple modes of action. " 01/01/2007 - "Genetic variation at the apolipoprotein A-V locus, recently discovered proximal to the APOA1/C3/A4 gene cluster, is associated with elevated triglyceride concentrations, a risk factor for atherosclerosis. " 11/01/1997 - "[Apolipoprotein(a) as a test of atherosclerosis activity (review of literature)]." 09/08/1997 - "The Lp(a) concentration remained significantly higher in patients than in controls for most of the phenotypes, suggesting that both a high Lp(a) concentration and a different apolipoprotein (a) size distribution could be involved in the development of atherosclerosis in this population. " 09/08/1997 - "A case control study was undertaken to compare the distribution of apolipoprotein (a) phenotypes in patients suffering from atherosclerosis and undergoing coronary bypass surgery with the distribution observed in adequately selected controls. "
3.	Diabetes Mellitus 08/01/1999 - "Is apolipoprotein(a) a susceptibility gene for type I diabetes mellitus and related to long-term survival?" 01/01/1999 - "It furthermore discusses the observed association between the low molecular weight apolipoprotein(a) phenotype and Type I diabetes mellitus." 01/01/1999 - "[Genetic-epidemiological studies of apolipoprotein(a) polymorphism and its significance in nephrological diseases and type I diabetes mellitus]." 09/15/1997 - "To study the implications of Lp(a) in cerebrovascular disease (CVD) and diabetes mellitus (DM), we examined plasma Lp(a) levels and molecular weights of apolipoprotein(a) [apo(a)] in 118 patients with CVD, and 125 cases with DM. " 10/01/2003 - "Apoprotein(a) phenotypes and plasma lipoprotein(a) concentration in patients with diabetes mellitus."
4.	Vascular Diseases (Vascular Disease) 08/21/2012 - "The purpose of this study is investigate the effects of variants in the apolipoprotein(a) gene (LPA) on vascular diseases with different atherosclerotic and thrombotic components. " 01/01/1994 - "Apolipoprotein (a) levels in patients with type 1 diabetes mellitus are unrelated to metabolic control or vascular disease." 05/11/2010 - "Apolipoprotein(a) isoforms and the risk of vascular disease: systematic review of 40 studies involving 58,000 participants." 01/01/1995 - "Apolipoprotein(a) [apo(a)] isoform distribution was similar between the groups, but those with vascular disease had higher Lp(a) levels in the S2, S3/S4 and S4 isoform types. " 06/01/2009 - "Peptides that resemble in physicochemical properties the helices of apoprotein A-I, the major protein of atheroprotective HDL, show promise for the treatment of atherosclerosis-related vascular disease. "
5.	Chronic Kidney Failure (Chronic Renal Failure) 04/01/2007 - "Marked decrease of apolipoprotein A-V in both diabetic and nondiabetic patients with end-stage renal disease." 11/26/2002 - "Small apolipoprotein(a) size predicts mortality in end-stage renal disease: The CHOICE study." 03/01/1992 - "Increased serum apolipoprotein(a) in patients with chronic renal failure treated with continuous ambulatory peritoneal dialysis." 09/01/1994 - "Apolipoprotein(a) phenotypes predict the risk for carotid atherosclerosis in patients with end-stage renal disease." 05/01/1997 - "Lipoprotein(a) and apolipoprotein(a) phenotypes in patients with end-stage renal disease."

Related Drugs and Biologics

1.	Protein Isoforms (Isoforms)
2.	Apolipoproteins A
3.	Lipoprotein(a)
4.	Aspirin (Acetylsalicylic Acid)
5.	Apolipoproteins
6.	Peptides
7.	Lipoproteins (Lipoprotein)
8.	Cholesterol
9.	Triglycerides (Triacylglycerol)
10.	HDL Cholesterol

Related Therapies and Procedures

1.	Electroacupuncture
2.	Drug Therapy (Chemotherapy)
3.	Renal Dialysis (Hemodialysis)
4.	Kidney Transplantation
5.	Transplants (Transplant)